We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ondine Biomed | LSE:OBP | London | Ordinary Share | CA68234M1068 | COM SHS NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMOBP
Ondine Biopharma Corporation: AIM Notification
FOR: ONDINE BIOPHARMA CORPORATION
TSX, AIM SYMBOL: OBP
April 13, 2010
Ondine Biopharma Corporation: AIM Notification
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 13, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP)
("Ondine" or the "Company") today announces the following transaction by a Director of the Company:
/T/
=--------------------------------------------------------------------------
Name Merrill Biel
=--------------------------------------------------------------------------
Relationship to the Company Director
=--------------------------------------------------------------------------
Date the transaction was reported to the Company April 9, 2010
=--------------------------------------------------------------------------
Nature of the transaction Options issued which
entitle the holder to
purchase common shares
under the Company's
stock option plan
=--------------------------------------------------------------------------
Grant date April 9, 2010
=--------------------------------------------------------------------------
Expiry date April 9, 2015
=--------------------------------------------------------------------------
Number of options issued 200,000
=--------------------------------------------------------------------------
Exercise price per option, each option
is exercisable into one common share Cdn. $0.075
=--------------------------------------------------------------------------
Price per security issued in this transaction Nil
=--------------------------------------------------------------------------
Nature and extent of the above's interest 100% direct
in the transaction ownership interest
=--------------------------------------------------------------------------
Close period No
=--------------------------------------------------------------------------
Additional information The options vest in stages
during the first year
after the date of grant
=--------------------------------------------------------------------------
/T/
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Ondine Biopharma Corporation
Carolyn Cross
Chairman and CEO
(604) 669-0555
ccross@ondinebiopharma.com
www.ondinebiopharma.com
OR
Canaccord Adams Ltd.
Ryan Gaffney
Nominated Adviser
+4420 7050 6500
Ondine Biopharma Corporation
1 Year Ondine Biomed Chart |
1 Month Ondine Biomed Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
